Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2007-06-19
2007-06-19
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C435S005000, C435S235100
Reexamination Certificate
active
10484236
ABSTRACT:
The multivalent strains of bacteriophages, methods of obtaining these and their use in the treatment of bacterial infections, particularly those of drug-resistant bacterial strains, especially arising in mucoviscidosis patients, are provided.
REFERENCES:
patent: 4118315 (1978-10-01), Fletcher et al.
patent: 4797363 (1989-01-01), Teodorescu et al.
patent: 4828999 (1989-05-01), Jackson
patent: 5470573 (1995-11-01), Lubitz et al.
patent: 5824468 (1998-10-01), Scherer et al.
patent: 5846604 (1998-12-01), Caldwell
patent: 6027930 (2000-02-01), Borrebaeck
patent: 6121036 (2000-09-01), Ghanbari et al.
patent: 6322783 (2001-11-01), Takahashi
patent: 6461608 (2002-10-01), Averback et al.
patent: 6482632 (2002-11-01), Agrawal et al.
patent: 6696295 (2004-02-01), Westpheling et al.
patent: 6783930 (2004-08-01), Pelletier et al.
patent: 6787360 (2004-09-01), Agrawal et al.
patent: 2002/0127547 (2002-09-01), Miller
patent: 2003/0216338 (2003-11-01), Merril et al.
patent: 2004/0247569 (2004-12-01), Morris et al.
patent: 2005/0107326 (2005-05-01), Norris et al.
patent: 2005/0175991 (2005-08-01), Sulakvelidze et al.
patent: 2005/0260171 (2005-11-01), Ghanbari et al.
patent: 192212 (1979-08-01), None
patent: 19828596 (1999-02-01), None
patent: 0290295 (1988-11-01), None
patent: 0414304 (1991-02-01), None
patent: 0510907 (1992-10-01), None
patent: 829266 (1960-03-01), None
patent: 2253859 (1992-09-01), None
patent: 2285684 (1995-07-01), None
patent: 2109055 (1998-04-01), None
patent: 543260 (1984-04-01), None
patent: WO 90/03122 (1990-04-01), None
patent: WO 94/06931 (1994-03-01), None
patent: WO 95/05454 (1995-02-01), None
patent: WO 96/07329 (1996-03-01), None
patent: WO 98/08944 (1998-03-01), None
patent: WO 01/00786 (2001-01-01), None
patent: WO 01/09370 (2001-02-01), None
Alonso, MC e tal, Microbiologia Sem. vol. 10, pp. 285-296, 1994, A direct membrane filter method for enumberating somatic coliphages in driinking water.
Konopka, M et al, ACTA Microbiologica Polonica, 1996, vol. 45, No. 3-4, pp. 269-278, Phenotyping methods in epidemiological analysis of EpidemicStaphylococcus aureusstrains.
Sulakvelidze, A et al, Antimicrobial Agents and Chemotherapy, Mar. 2001, vol. 45(3),pp. 649-659, Bacteriophage therapy, Minireview.
Burroughs, NJ et al, Applied and Environmental Microbiology, Sep. 2000, vol. 66(9), pp. 3868-3877, Mathematical Analysis of growth and interaction dynamics of Streptomyces and a bacteriophage in soil.
Oakley, TH et al, Evolution, vol. 54(2), pp. 397-405, 2000.
(abstract only), German, Gregory John, Ph.D dissertation, 2003, Receptor interaction and genomic sequence of the ToIC and lipopolysaccharide specific bacteriophage, vol. 64, abstrac 09-6, p. 4186.
Payne et al, Clinical pharmacology and therapeutics, Sep. 200, pp. 225-230: Phage therapy: The peculier kinetics of self-replicaiting pharmaceuticals.
Chibani-Chennoufi, S et al, Antimicrobial Agents and Chemotherapy, Jul. 2004, pp. 2558-2569, vol. 48(7).
Skurnik, Mikael et al, International Journal of Medical Microbiology, vol. 296, pp. 5-14, 2006, Phage Therapy, Facts and fiction.
Wendlinger, Get al, Microbiology, Apr. 1996, vol. 142(4)pp. 985-992.
Weld, Richard J., Journal of Theoretical Biology, Vo. 227, pp. 1-11, 2004.
Bohannan, BJM et al, Ecology Letters, 2000, vol. 3, pp. 362-377.
Summers, William C, Bacteriophage Therapy, Annu. Rev. Microbiol., 2001, vol. 55, pp. 437-451.
Tejedor, C et al, Infection and Immunity, Apr. 1982, vol. 36(1), pp. 440-441.
(Best copy) Souza, KA et al, Journal of Virology, vol. 9(5) pp. 851-856, May 1972.
Pantucek, Roman et al, Virology, vol. 246, pp. 241-252, 1998.
Burroughs, NJ et al, App. Environ. Microbiology, Sep. 2000, vol. 66(9), pp. 3868-3877.
Giese, Michael et al, Am. J. of Ophthalmology, vol. 122(2), pp. 245(10), Aug. 1996.
Darsavelidze et al., “The Development of a Standard System for the Determination of the Lytic Activity of Pseudomonas-Aeruginosa Bacteriophage,”Izvestiya Akademii Nauk Gruzinskol SSR Seriya Biologicheskaya16:330-335 (1990).
Garsevanishvili, “Certain Methodological Aspects of the Use of Inhalation of a Polyvalent Bacteriophage in the Treatment of Pneumonia of Young Children,”Pediatrlia53:65-66 (1974).
Seidova et al., “Prevention of Suppuration in Open Fractures,”Vestn. Khir. Im. I. I. Grek.117:76-78 (1976).
{dot over (S)}lopek et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections. I. General Evaluation of the Results,”Arch. Immunol. Ther. Exp.(Warsz.) 31:267-291 (1983).
{dot over (S)}lopek et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections. II. Detailed Evaluation of the Results,”Arch. Immunol. Ther. Exp.(Warsz.) 31:293-327 (1983).
{dot over (S)}lopek et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections. III. Detailed Evaluation of the Results Obtained in Further 150 Cases,”Arch. Immunol. Ther. Exp.(Warsz.) 32:317-335 (1984).
{dot over (S)}lopek et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections. IV. Evaluation of the Results Obtained in 370 Cases,”Arch. Immunol. Ther. Exp.(Warsz.) 33:219-240 (1985).
{dot over (S)}lopek et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections. V. Evaluation of the Results Obtained in Children,”Arch. Immunol. Ther. Exp.(Warsz.) 33:241-259 (1985).
{dot over (S)}lopek et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections in the Years 1981-1986,”Arch. Immunol. Ther. Exp.(Warsz.) 35:569-583 (1987).
Sulakvelidze et al., “Bacteriophage Therapy,”Antimicrob. Agents Chemother.45:649-659 (2001).
Weber-Dabrowska et al., “Effective Phage Therapy Is Associated with Normalization of Cytokine Production by Blood Cell Cultures,”Arch. Immunol. Ther. Exp.(Warsz.) 48:31-37 (2000).
Weber-Dabrowska et al., “Bacteriophage Therapy of Bacterial Infections: An Update of Our Institute's Experience,”Arch. Immunol. Ther. Exp.(Warsz.) 48:547-551 (2000).
Boratynski Janusz
Gorski Andrzej
Lusiak-Szelachowska Marzanna
Mulczyk Marian
Syper Danuta
Clark & Elbing LLP
Instytut Immunologii I Terapii Doswiadczal-Nej Pan
Navarro Mark
Portner Ginny Allen
LandOfFree
Methods of polyvalent bacteriophage preparation for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of polyvalent bacteriophage preparation for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of polyvalent bacteriophage preparation for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861502